Company Information

Company Profile

MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX) is a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the clinical development of products to address unmet medical needs for the treatment of cancer. Our antibody HuMab-5B1, is a fully human IgG1 monoclonal antibody (mAb) that targets sialyl Lewis A (sLea), an epitope on CA19-9. CA19-9 is expressed in over 90% of pancreatic cancer (PDAC) and in other diseases including small cell lung, colon and other GI cancers. HuMab-5B1 when used as a therapeutic agent, designated as MVT-5873, has been studied in patients with pancreatic cancer and other CA19-9 positive tumors. MVT-5873 has recently completed a monotherapy Phase 1a clinical trial in 32 patients. The HuMab-5B1 antibody coupled with a PET imaging agent, designated as MVT-2163, has recently completed a 12 patient Phase 1a clinical trial as well. With our collaborators including Memorial Sloan Kettering Cancer Center, Rockefeller University, Sarah Cannon Research Institute, HonorHealth and Imaging Endpoints, we have treated 50 patients with either our therapeutic antibody (MVT-5873) or our PET imaging diagnostic product (MVT-2163), and demonstrated early safety, specificity for the target and a potential efficacy signal. Data from these two studies have accelerated development of the Company's Radioimmunotherapy (RIT) product, designated as MVT-1075, and patient dosing in a Phase 1 clinical study has commenced for our lead development program which combines the targeting specificity of the HuMab-5B1 antibody with the clinically proven potency of a radionuclide.   

Contact Information

Investor Relations
Jenene Thomas Communications
Jenene Thomas
T: 908-938-1475
jtc@jenenethomascommunications.com

Company Contact
MabVax Therapeutics Holdings, Inc.
11535 Sorrento Valley Road
San Diego, CA 92121